New York, N.Y., October 22, 2012 — Lauren Sciences LLC, a privately-held biotechnology company furthering development of its new V-Smart™ nanovesicle platform technology, announced today that it has been independently recognized as a leading drug delivery company, and its V-Smart™ platform selected as a significant advance in blood brain barrier (BBB) technology, by Datamonitor Healthcare.
Datamonitor Healthcare (part of Informa plc), a leading provider of online database and analysis services for the Pharmaceuticals and Healthcare industries, has just published the report “Central Nervous System Drug Delivery Specialists” in which Lauren Sciences LLC is identified as one of the leading drug delivery companies with innovative technologies designed to enhance central nervous system (CNS) drug delivery, one of only 15 companies chosen for inclusion in the report and selected to be profiled.
Datamonitor Healthcare has also identified Lauren Sciences’ V-Smart™ technology as exemplifying significant recent advances in BBB technology, one of only four chosen as innovative technologies that enhance the penetration of CNS drugs, for inclusion in the report “Delivery Across the Blood-Brain Barrier” and selected to be highlighted as a case study.
“The inclusion of Lauren Sciences in the Datamonitor Healthcare reports can be justifiably claimed as independent acknowledgement of the important potential of Lauren Sciences and our V-Smart™ drug delivery technology,” said Susan Rosenbaum, J.D., Chairman and Chief Executive Officer of Lauren Sciences. “We expect that this recognition will foster new research collaborations in the healthcare industry for Lauren Sciences and, thus, further development of our novel ‘quick-to-clinic’ V-Smart™ therapeutics for CNS-disease patients.”